References
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA: Canc J
Clinician 2012, 62(1):10–29.
Kokko LL, Hurme S, Maula SM, Alanen K, Grenman R, Kinnunen I, Ventela S:
Significance of site-specific prognosis of cancer stem cell marker CD44
in head and neck squamous cell carcinoma. Oral Oncol 2011,
47(6):510–516.
Institute NC. Cancer Stat Facts: Larynx Cancer Surveillance,
Epidemiology, and Results (SEER) database. 2016.
Wolf GT, Fisher SG, Hong WK, et al. Induction chemotherapy plus
radiation comparedd with surgery plus radiation in patients with
advanced laryngeal cancer. N Engl J Med 1991;324(24):1685–90.
Ries LA, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al.
SEER cancer statistics review, 1975-2003. Bethesda, MD: National Cancer
Institute; 2006.
Mendenhall WM, Amdur RJ, Morris CG, Hinerman RW. T1-T2N0 squamous cell
carcinoma of the glottic larynx treated with radiation therapy. J Clin
Oncol. 2001;19:4029-36.
Karatzanis AD, Psychogios G, Zenk J, Waldfahrer F, Hornung J, Velegrakis
GA, et al. Comparison among different available surgical approaches in
T1 glottic cancer. Laryngoscope. 2009; 119:1704-8.
Silver CE, Beitler JJ, Shaha AR, Rinaldo A, Ferlito A. Current trends in
initial management of laryngeal cancer: the declining use of open
surgery. Eur Arch Otorhinolaryngol. 2009;266: 1333-52.
Yoo J, Lacchetti C, Hammond JA, Gilbert RW; Head and Neck Cancer Disease
Site Group. Role of endolaryngeal surgery (with or without laser) versus
radiotherapy in the managementt of early (T1) glottic cancer: a
systematic review. Head Neck. 2014;36:1807-19.
Mendenhall WM, Werning JW, Hinerman RW, Amdur RJ, Villaret DB.
Management of T1-T2 glottic carcinomas. Cancer. 2004;100:1786-92.8.
Abdurehim Y, Hua Z, Yasin Y, Xukurhan A, Imam I, Yuqin F.Transoral laser
surgery versus radiotherapy: systematic review and meta-analysis for
treatment options of T1a glottic cancer. Head Neck. 2012;34:23-33.
Wiernik G, Millard PR, Haybittle JL. The predictive value of
histological classification into degrees of differentiation of squamous
cell carcinoma of the larynx and hypopharynx compared with the survival
of patients. Histopathology 1991; 19:411-417.
Westerbeek HA, Mooi WJ, Hilgers FJ, Baris G, Begg AJ, Balm AJ. Ploidy
status and the response of T1 glottic carcinoma to radiotherapy. Clin
Otolaryngol 1993: 18:98-101.
Gallo O, Libonati GA, Gallina E, Fini-Storchi O, Giannini A, Urso C,
Bondi R. Langerhans cells related to prognosis in patients with
laryngeal carcinoma. Arch Otolaryngol Head Neck Surg 1991,
117:1007-1010.
Lobo NA, Shimono Y, Qian D, Clarke MF: The biology of cancer stem cells.
Ann Rev Dev Biol 2007, 23:675–699.
Bomken S, Fiser K, Heidenreich O, Vormoor J: Understanding the cancer
stem cell. Br J Canc 2010, 103(4):439–445.
Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, Tsai TH, Chou SH, Chien CS,
Ku HH, Lo JF: Positive correlations of Oct-4 and Nanog in oral cancer
stem-like cells and high-grade oral squamous cell carcinoma. Clin Canc
Res: Offic J Am Assoc Canc Res 2008, 14(13):4085–4095.
Yu CC, Chang YC: Enhancement of cancer stem-like and
epithelial-mesenchymall transdifferentiation property in oral epithelial
cells with long-term nicotine exposure: reversal by targeting SNAIL.
Toxicol Appl Pharmacol 2013, 266(3):459–469.
Chen YS, Wu MJ, Huang CY, Lin SC, Chuang TH, Yu CC, Lo JF: CD133/Src
axis mediates tumor initiating property and epithelial-mesenchymal
transition of head and neck cancer. PloS One 2011, 6(11):e28053.
Trapasso S, Allegra E: Role of CD44 as a marker of cancer stem cells in
head and neck cancer. Biol: Targets Ther 2012, 6:379–383.
Joshua B, Kaplan MJ, Doweck I, Pai R, Weissman IL, Prince ME, Ailles LE:
Frequency of cells expressing CD44, a head and neck cancer stem cell
marker: correlation with tumor aggressiveness. Head Neck 2012,
34(1):42–49.
Chikamatsu K, Takahashi G, Sakakura K, Ferrone S, Masuyama K:
Immunoregulatory properties of CD44+ cancer stem-like cells in squamous
cell carcinoma of the head and neck. Head & neck 2011, 33(2):208–215.
Amin M, Edge S, Greene F, et al. AJCC cancer staging manual. Eighth ed.
New York: Springer; 2017.
Chen C, Wei Y, Hummel M, Hoffmann TK, Gross M, Kaufmann AM, et al.
Evidence for epithelial-mesenchymal transition in cancer stem cells of
head and neck squamous cell carcinoma. PLoS ONE. 2011;6(1):e16466.
Greco N, Schott T, Mu X, Rothenberg A, Voigt C, McGough RL III, et al.
ALDH activity correlates with metastatic potential in primary sarcomas
of bone. J Cancer Ther. 2014;5(4):331–8.
Chen YC, Chen YW, Hsu HS, Tseng LM, Huang PI, Lu KH, et al. Aldehyde
dehydrogenase 1 is a putative marker for cancer stem cells in head and
neck squamous cancer. Biochem Biophys Res Commun. 2009;385(3):307–13.
Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P,
et al. Identification of a subpopulation of cells with cancer stem cell
properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci
U S A. 2007 Jan 16;104(3):973-8.
Al-Assar O, Muschel RJ, Mantoni TS, McKenna WG, Brunner TB. Radiation
response of cancer stem-like cells from established human cell lines
after sorting for surface markers. Int J Radiat Oncol Biol Phys.
2009;75(4):1216–25.
Zhou C, Sun B. The prognostic role of the cancer stem cell marker
aldehyde dehydrogenase 1 in head and neck squamous cell carcinomas: a
meta-analysis. Oral Oncol. 2014;50(12):1144–8.
Lopez-Gonzalez A, Salas C, Provencio M, Cordoba M, Gamallo C. Aldehyde
dehydrogenases in early stage lung cancer: nuclear expression. Clin
Transl Oncol. 2014;16(10):931–4.